Valneva Signs an Agreement to Acquire Dukoral Vaccine
Advertisement
Valneva SE announced that it has entered into a Sale and Purchase Agreement with Crucell Holland B.V. to acquire Crucell Sweden AB and all assets, licenses and privileges related to Dukoral®, a vaccine against cholera and traveler’s diarrhea caused by ETEC, as well as a Nordics vaccine distribution business of the seller
and its affiliates.
The agreement entails in particular the purchase of the manufacturing site in Solna (Sweden) and will comprise approximately 115 employees (FTE’s). The total transaction consideration amounts to EUR 45 million.